Serum calpain-5 as a biomarker for disease severity and clinical outcomes in COVID-19 patients.

Miao HL, Liu MX, Cao W, Wu GQ, Li L, Cai X, Wang SH, Fu L, Fei J, Zhang F

Open source

DOI
10.1186/s12879-026-14115-7
Published
2026 Jul 31
Container
BMC infectious diseases
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12879-026-14115-7,
  title = {Serum calpain-5 as a biomarker for disease severity and clinical outcomes in COVID-19 patients.},
  author = {Miao HL and Liu MX and Cao W and Wu GQ and Li L and Cai X and Wang SH and Fu L and Fei J and Zhang F},
  year = {2026},
  journal = {BMC infectious diseases},
  doi = {10.1186/s12879-026-14115-7},
  url = {https://doi.org/10.1186/s12879-026-14115-7}
}

RIS

TY  - JOUR
TI  - Serum calpain-5 as a biomarker for disease severity and clinical outcomes in COVID-19 patients.
AU  - Miao HL
AU  - Liu MX
AU  - Cao W
AU  - Wu GQ
AU  - Li L
AU  - Cai X
AU  - Wang SH
AU  - Fu L
AU  - Fei J
AU  - Zhang F
PY  - 2026
JO  - BMC infectious diseases
DO  - 10.1186/s12879-026-14115-7
UR  - https://doi.org/10.1186/s12879-026-14115-7
ER  - 

APA

HL, M., MX, L., W, C., GQ, W., L, L., X, C., SH, W., L, F., J, F., & F, Z. (2026). Serum calpain-5 as a biomarker for disease severity and clinical outcomes in COVID-19 patients.. BMC infectious diseases. https://doi.org/10.1186/s12879-026-14115-7

Source records